Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-303 Red Blood Cells- Test · 1 trial · 1 indication
The mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups
The frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.
| Arm | Type | Description |
|---|---|---|
| S-303 Treated Red Blood Cells | EXPERIMENTAL | Patients receive S-303 treated red blood cells (RBCs). |
| Conventional, untreated Red Blood Cells | ACTIVE_COMPARATOR | Patients receive conventional, untreated red blood cells (RBCs). |
| Name | Type | Description |
|---|---|---|
| S-303 Red Blood Cells (RBCs) - Test | BIOLOGICAL | - |
| Conventional, untreated red blood cells (RBCs) - Control | BIOLOGICAL | - |
Inclusion Criteria: 1. Age ≥18 years, of either gender. 2. Must be willing to use an acceptable form of contraceptive while on study (as approved by the Investigator or designee) 3. Must be readily available by telephone 4. Must provide an informed consent for study participation and have signed an...
S-303 Red Blood Cells is an investigational pathogen-reduced red blood cell product being studied for transfusion support in patients with acute anemia. It is designed to assess post-infusion viability of treated red blood cells and their safety and efficacy in patients requiring transfusion support.
S-303 Red Blood Cells is being developed by Cerus Corporation, a biopharmaceutical company traded on NASDAQ under the ticker symbol CERS. The company is conducting clinical studies to evaluate the product's viability and efficacy in transfusion settings.
S-303 Red Blood Cells is in Phase 3 clinical development. A Phase 3 study has been completed to evaluate its safety and efficacy in patients with acute anemia requiring transfusion support. The product remains investigational and is not yet approved for commercial use.
S-303 Red Blood Cells has been studied in two completed trials. NCT01711346 assessed the recovery and lifespan of radiolabeled autologous S303-treated red blood cells in healthy volunteers. NCT01716923 evaluated safety and efficacy in patients with acute anemia requiring transfusion support.
Yes, S-303 Red Blood Cells is also referred to as S303 RBCs. The product is a pathogen-reduced red blood cell preparation developed by Cerus Corporation, and clinical trials use the S303 RBCs terminology to describe the investigational treatment.